bpc-157 clinical trial 2025 results for Mental Health: What 30 Years of Research Shows BPC-157 Injectable Peptide for Healing
Description
In preclinical models, Dihexa demonstrated superior pharmacokinetic properties, including good oral activity and effective BBB penetration, along with enhanced metabolic stability with a half-life of 335.5 minutes
doi: 10.1186/s12893-017-0216-z
Note that these two documented starting doses are worlds apart in size 150 mcg versus 2.5 mg is a roughly 17-fold difference
Optimizing B12 levels may help support more consistent serotonin synthesis even during periods of reduced sunlight
Although 240 follicles were tested, they came from only 3 volunteers for the organ culture component
